OBJECTIVES: Golimumab (GLM) is a monthly self-injected anti-tumor necrosis factor alpha therapy providing once-monthly dosing for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). This study assesses the baseline characteristics and utilization patterns of patients who received GLM. METHODS: We performed a retrospective database analysis of The MarketScan® Research Database from Thomson Reuters. This database contains individual-level, de-identified, healthcare claims information from employers, health plans, hospitals, Medicare, and Medicaid. A total of 29,774 patients in this database had a diagnosis of either RA, PsA or AS and at least one biologic on record and met the following inclusion criteria:  ≥18 years of age at the time of the first diagnosis. From this sample, a total of 174 patients had at least one prescription record for GLM. RESULTS: A total of 174 patients receiving GLM were identified as meeting all the inclusion criteria; with 128 (RA), 30 (PSA), and 16 (AS). The mean age was 48 years and 75% of the sample was female. A total of 155 (89%) patients were bio-experienced and 19 (11%) were bio-naïve before initiating golimumab. A total of 111 patients received at least two GLM doses. Of the patients with two or more GLM doses, the median and mean ±SD dosing interval was 29.5 days and 33.65 ± 15.56 days. When looking at biologic naïve patients the median and mean ±SD dosing interval was 30 days and 35.37 ± 17.63 days versus biologic experienced patients with a dosing interval of 29 days and 33.15 ± 15.00 days. CONCLUSIONS: In the MarketScan database, the majority of patients with a prescription for GLM was female and had prior biologic experience. GLM median and mean doses were 29.5 and 33.37 days respectively. Previous biologics experience did not significantly change the GLM dosing patterns.